Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)

Rhea-AI Filing Summary

LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the company’s 2020 Independent Director Equity Incentive Plan. These units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting, subject to plan and award terms. Following this grant, Love directly holds 58,393 Class A Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LOVE TED W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	--

Holdings After Transaction: Class A Ordinary Shares — 58,393 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 4,545 shares Grant price: $0.00 per share Shares owned after grant: 58,393 shares +1 more

4 metrics

RSUs granted 4,545 shares Restricted stock unit award to director Ted W. Love

Grant price $0.00 per share Equity award under 2020 Independent Director Equity Incentive Plan

Shares owned after grant 58,393 shares Direct holdings following reported transaction

Vesting schedule 100% cliff vest Earlier of one-year from grant or next annual shareholder meeting

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, vest 100%, annual meeting of the Issuer's shareholders

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

vest 100% financial

"that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary"

annual meeting of the Issuer's shareholders financial

"and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOVE TED W

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	58,393	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Ted W. Love	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Royalty Pharma (RPRX) report in this Form 4 for Ted W. Love?

The Form 4 reports an equity grant to director Ted W. Love. He received 4,545 Class A Ordinary Shares via a restricted stock unit award under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan, increasing his direct holdings to 58,393 shares.

How many Royalty Pharma (RPRX) shares were granted to Ted W. Love?

Ted W. Love was granted 4,545 Class A Ordinary Shares. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase, and was issued as restricted stock units under the company’s independent director plan.

What are the vesting terms of Ted W. Love’s new Royalty Pharma (RPRX) RSUs?

The RSUs are scheduled to vest 100% in a single tranche. Vesting occurs on the earlier of the one-year anniversary of the grant date or the date of Royalty Pharma’s next annual shareholder meeting, subject to the equity plan and the related award agreement.

How many Royalty Pharma (RPRX) shares does Ted W. Love own after this transaction?

After the grant, Ted W. Love directly holds 58,393 Class A Ordinary Shares. This total includes the newly awarded 4,545 restricted stock units reported in the Form 4, reflecting his updated direct ownership position in Royalty Pharma.

Was Ted W. Love’s Royalty Pharma (RPRX) transaction an open-market buy or a compensation grant?

The transaction was a compensation-related grant, not an open-market buy. It is coded as an “A” transaction, described as a grant, award, or other acquisition, with a price of $0.00 per share under the 2020 Independent Director Equity Incentive Plan.